Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Hum Vaccin Immunother ; 17(8): 2808-2813, 2021 08 03.
Article in English | MEDLINE | ID: covidwho-1114800

ABSTRACT

Conventional vaccines to combat COVID-19 through different approaches are at various stages of development. The complexity of COVID-19 such as the potential mutations of the virus leading to antigenic drift and the uncertainty on the duration of the immunity induced by the vaccine have hampered the efforts to control the COVID-19 pandemic. Thus, we suggest an alternative interim treatment strategy based on biological response modifier glucans such as the Aureobasidium pullulans AFO-202-derived ß-glucan, which has been reported to induce trained immunity, akin to that induced by the Bacille Calmette-Guérin vaccine, by epigenetic modifications at the central level in the bone marrow. These ß-glucans act as pathogen-associated molecular patterns, activating mucosal immunity by binding with specific pathogen recognition receptors such as dectin-1 and inducing both the adaptive and innate immunity by reaching distant lymphoid organs. ß-Glucans have also been used as immune adjuvants for vaccines such as the influenza vaccine. Therefore, until a conventional vaccine is widely available, an orally consumable vaccine adjuvant that acts like biosimilars, termed as the wide-spectrum immune-balancing food-supplement-based enteric (ß-WIFE) vaccine adjuvant approach, with well-reported safety is worth in-depth investigation and can be considered for a clinical trial.


Subject(s)
Biosimilar Pharmaceuticals , COVID-19 , beta-Glucans , Adjuvants, Immunologic , BCG Vaccine , Humans , Immunity, Innate , Pandemics , SARS-CoV-2 , Spouses
2.
Front Immunol ; 11: 1548, 2020.
Article in English | MEDLINE | ID: covidwho-687591

ABSTRACT

Background: The COVID-19 pandemic has been causing varying severities of illness. Some are asymptomatic and some develop severe disease leading to mortality across ages. This contrast triggered us explore the causes, with the background that a vaccine for effective immunization or a drug to tackle COVID-19 is not too close to reality. We have discussed strategies to combat COVID-19 through immune enhancement, using simple measures including nutritional supplements. Discussion: A literature search on mortality-related comorbid conditions was performed. For those conditions, we analyzed the pro-inflammatory cytokines, which could cause the draining of the immune reservoir. We also analyzed the immune markers necessary for the defense mechanism/immune surveillance against COVID-19, especially through simple means including immune enhancing nutritional supplement consumption, and we suggest strategies to combat COVID-19. Major comorbid conditions associated with increased mortality include cardiovascular disease (CVD), diabetes, being immunocompromised by cancer, and severe kidney disease with a senile immune system. Consumption of Aureobasidium pullulans strain (AFO-202) beta 1,3-1,6 glucan supported enhanced IL-8, sFAS macrophage activity, and NK cells' cytotoxicity, which are major defense mechanisms against viral infection. Conclusion: People with co-morbid conditions who are more prone to COVID-19-related deaths due to immune dysregulation are likely to benefit from consuming nutritional supplements that enhance the immune system. We recommend clinical studies to validate AFO-202 beta glucan in COVID-19 patients to prove its efficacy in overcoming a hyper-inflammation status, thus reducing the mortality, until a definite vaccine is made available.


Subject(s)
Betacoronavirus , Cardiovascular Diseases/epidemiology , Coronavirus Infections/epidemiology , Coronavirus Infections/immunology , Diabetes Mellitus/epidemiology , Dietary Supplements , Neoplasms/epidemiology , Pneumonia, Viral/epidemiology , Pneumonia, Viral/immunology , Renal Insufficiency, Chronic/epidemiology , Actinobacteria/chemistry , Biomarkers/blood , COVID-19 , Cardiovascular Diseases/immunology , Comorbidity , Coronavirus Infections/diet therapy , Coronavirus Infections/mortality , Cytokines/blood , Diabetes Mellitus/immunology , Humans , Immunocompromised Host , Neoplasms/immunology , Pandemics , Pneumonia, Viral/diet therapy , Pneumonia, Viral/mortality , Renal Insufficiency, Chronic/immunology , SARS-CoV-2 , beta-Glucans/pharmacology , beta-Glucans/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL